SCHEMBL3013317

SCHEMBL3013317

Cc1ccc(S(=O)(=O)N2CCN(c3nc(Cc4ccc(Cl)cc4Cl)cs3)CC2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 3/20 0.51
ALDH1A1 P00352 2/20 0.51
HTT P42858 2/20 0.51
KDM4E B2RXH2 1/20 0.51
GBA1 P04062 1/20 0.47
POLB P06746 1/20 0.46
SMN1; SMN2 Q16637 3/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
KMT2A Q03164 3/20 0.44
MEN1 O00255 1/20 0.44
HSD11B1 P28845 1/20 0.44
ABL1 P00519 1/20 0.44
BCR P11274 1/20 0.44
TP53 P04637 1/20 0.43
TSHR P16473 2/20 0.42
USP2 O75604 2/20 0.42
LMNA P02545 1/20 0.42
MAPK1 P28482 1/20 0.42
HDAC3 O15379 1/20 0.42
HDAC4 P56524 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3002640 0.94 POLB (0.52) NPSR1ALDH1A1HTTKDM4EGBA1
SCHEMBL3003729 0.90 ALDH1A1 (0.58) NPSR1ALDH1A1HTTGBA1POLB
SCHEMBL3010912 0.90 POLB (0.46) NPSR1ALDH1A1HTTKDM4EGBA1
SCHEMBL3017503 0.89 HSD11B1 (0.53) NPSR1ALDH1A1HTTGBA1POLB
SCHEMBL3008163 0.89 POLB (0.45) NPSR1ALDH1A1HTTKDM4EGBA1
SCHEMBL3004828 0.89 POLB (0.44) NPSR1ALDH1A1HTTKDM4EGBA1
SCHEMBL3009212 0.88 POLB (0.45) NPSR1ALDH1A1HTTKDM4EGBA1
SCHEMBL3652531 0.88 ALDH1A1 (0.41) NPSR1ALDH1A1HTTKDM4EGBA1
SCHEMBL3010733 0.88 ALDH1A1 (0.48) NPSR1ALDH1A1HTTKDM4EGBA1
SCHEMBL3006852 0.88 ALDH1A1 (0.48) NPSR1ALDH1A1HTTKDM4EGBA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA NPSR1 764/4885ALDH1A1 3510/4885HTT 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.